Unit - 2 of Hyderabad-based Divi's Laboratories Ltd has received six observations from USFDA. The Vizag unit was inspected by USFDA from September 11 to September 19, 2017.
"This inspection was for full cGMP and verification of all corrective actions proposed against the previous inspection observations. All previous observations have been confirmed as completed and resolved,'' the company said in an update.
On completion of this inspection, Divi's had received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time, it added.
The company's scrip ended higher by 9.13 per cent at Rs 942.75 on the Bombay Stock Exchange on Wednesday.